Search

everythinglearnresearchcommunity

for

Search:↓

Hair cloning is unlikely to be available soon, with estimates ranging from 10 to 20 years away. Current treatments like Minoxidil, finasteride, and RU58841 are still the main options.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

A 17-year-old is concerned about potential hair loss due to maternal genetics and wonders if treatments like Minoxidil, Finasteride, or RU58841 will be effective. They hope their paternal genetics will help prevent hair loss or make treatments more effective.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The conversation is about the claim that oral minoxidil can make hair grow on bones. The conclusion is that this claim is not true, as evidenced by the user's head being bald while the body is furry.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Transitioning genders humorously suggested for hair regrowth, noting some transgender individuals experience this. Discusses treatments like minoxidil, finasteride, and hormone therapy, but advises against transitioning solely for hair regrowth.

Genetics primarily determine hair loss, not lifestyle factors like diet, exercise, or habits. Treatments like finasteride and minoxidil are recommended, but ultimately, happiness should not depend on hair.

Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Bruce Willis's past comments on hair restoration and the progress of hair loss treatments like Minoxidil, Finasteride, and transplants. Users discuss the challenges of hair loss, the limited number of bald celebrities who are seen as role models, and the ongoing hope for future treatments.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and future hopes for hair cloning. Users express skepticism and frustration over current and future solutions.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

Shah Rukh Khan's hair at 60 is attributed to genetics, with speculation about using finasteride, minoxidil, or hair transplants. Some believe it's due to good genes, while others think he might use treatments or have had hair procedures.

A user trying to avoid an expensive hair transplant, and the replies suggesting they wait two years on treatment before deciding if they need a transplant or not.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

The conversation discusses a five-year hair maintenance routine involving microneedling, minoxidil, finasteride, biotin, and thickening shampoo. Opinions vary, with some seeing maintaining hair as a success and others expecting more visible results.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

A 25-year-old man is worried about his girlfriend noticing his balding and is frustrated by society's focus on looks. He uses minoxidil, finasteride, and dutasteride for hair loss and considers being honest with her.

Ronaldo's hairline remains sharp, while his brother's is receding. Opinions vary on whether Ronaldo uses treatments like finasteride or has had hair transplants, with some attributing his hairline to genetics and others to possible medical interventions.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation is a humorous discussion about hair loss, with users expressing envy towards an ancient figure who still has a full head of hair. No specific treatments are mentioned.

OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.

A 21-year-old woman diagnosed with male pattern baldness (MPB) who is considering treatments such as spironolactone, minoxidil and finasteride to address her hair loss. The user also discusses potential solutions for concealing the appearance of her thinning hair, such as wigs or haircuts.

The user is questioning why they are not experiencing hair loss like their family members. They are considering whether genetics or preventive treatments like Minoxidil, finasteride, or RU58841 might be influencing their hair retention.

User noticed scalp showing at 26, started finasteride at 28, and saw hair improvement by 30. Others shared similar experiences and advised trusting personal observations and trying finasteride early to prevent further hair loss.